Carregant...
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical pract...
Guardat en:
| Publicat a: | Trials |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124225/ https://ncbi.nlm.nih.gov/pubmed/27887632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-016-1675-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|